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may result in sudden death from cardiac autonomic 
neuropathy 2〜4） or require amputation of the lower ex-
tremities due to impairment of the peripheral auto-
nomic and sensory nerves, and therefore early and ac-
curate diagnosis of diabetic neuropathy is important in 
patients with diabetes. Subjective symptoms such as 
pain and numbness of the foot is helpful in diagnosis, 
but these symptoms weaken because of hypoesthesia 
with severe progression of neuropathy 1） and objective 
tests are required for accurate diagnosis. Measurement 
of nerve conduction velocity is a reliable and recom-
mended test for diabetic neuropathy because of its 
high sensitivity and reproducibility 5）, although this 
????????????
Among diabetic miocroangiopathies including neu-
ropathy, retinopathy and nephropathy, neuropathy 
generally develops at a relatively early stage after on-
set of diabetes1）．Progression of diabetic neuropathy 
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???????
The main purpose of the study was to investigate the association of median motor nerve conduction ve-
locity （MCV） and sural sensory nerve conduction velocity （SCV） with parameters related to diabetic com-
plications in patients with type 2 diabetes. A total of 263 patients hospitalized for glycemic control from 1999 
to 2006 who underwent single or multiple nerve conduction velocity tests （at least a right median MCV 
test） were enrolled in the study retrospectively. Right median MCV showed a significant negative correla-
tion with age and diabetic duration, and was also significantly negatively correlated with systolic blood pres-
sure （SBP） and log urinary albumin excretion （UAE）. Right median MCV showed strong positive correla-
tions with left median MCV and right median SCV, and significant but relatively mild positive correlations 
with right peroneal MCV and right sural SCV. In multiple regression analysis, only SBP and diabetic dura-
tion showed a significant association with right median MCV. Although right sural SCV showed significant 
negative correlations with SBP and log UAE, the correlations were relatively weak compared with those for 
right median MCV. Of 215 patients who underwent complete sural SCV measurements, right and left sural 
SCV were detected in 159 （74％） and 163 patients （76％）, respectively. In conclusion, these results suggest 
that median MCV is more closely associated with markers related to diabetic complications such as SBP or 
UAE, compared with sural SCV, but that sural SCV is more sensitive than median MCV for detection of dia-
betic neuropathy.
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method requires a lengthy measurement time and is 
somewhat invasive due to the pain caused by electrical 
stimulation.
Factors such as age, diabetic duration, glycemic con-
trol, blood pressure and circulating lipid concentrations 
appear to influence nerve conduction velocity in pa-
tients with type 2 diabetes, and these patients also fre-
quently develop hypertension or hyperlipidemia. How-
ever, the factors that are most important in the 
decrease of nerve conduction velocity in patients with 
type 2 diabetes have not been established clearly. 
Based on this background, the main purpose of the 
current study was to investigate the association of me-
dian motor nerve conduction velocity （MCV） and 
sural sensory nerve conduction velocity （SCV） with 
parameters related to diabetic complications in pa-
tients with type 2 diabetes. We also explored correla-
tions of median MCV with median SCV, peroneal MCV 
and sural SCV, and examined the correlation between 
median MCV on both sides.
????????????????????
Patients 
The study included 263 patients admitted to our hos-
pital for glycemic control from 1999 to 2006 who un-
derwent single or multiple nerve conduction velocity 
tests （at least a test of right median nerve conduction 
velocity）. These patients were enrolled in the study 
retrospectively based on our previous studies 6〜8）. Ex-
clusion of specific patients was not performed, but sev-
eral patients were enrolled redundantly among these 
studies and data from the latest study were used for 
these patients. The clinical characteristics and labora-
tory data for the 263 patients are shown in Table 1.
Methods
All tests were performed during hospitalization. Ve-
nous blood samples for biochemical tests were collect-
ed in the morning before breakfast after an overnight 
fast of at least 10 hours.
Measurement of MCV and SCV：MCV and SCV 
were measured in a supine position in a quiet room 
maintained at a temperature of about 25℃ . Median 
and peroneal MCV on both sides were determined at 
the elbow and wrist, and at the popliteal fossa and in-
side of the ankle, respectively. SCV was determined in 
the median and sural nerves on both sides. For mea-
surement of MCV, supramaximal stimuli were applied 
to the wrist and elbow or popliteal fossa and inside of 
the ankle, and the compound muscle action potential 
was measured with surface electrodes attached to the 
palm （for median MCV） or lateral portion of the sole 
of the foot （for peroneal MCV）. MCV was calculated 
from the motor nerve conduction time, which is the 
difference between the proximal and distal latencies 
divided by the distance from the elbow to the wrist 
（for median MCV） or from the popliteal fossa to the 
inside of the ankle （for peroneal MCV）. For SCV, a 
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???????　 Clinical characteristics and laboratory data of the 
type 2 diabetic subjects
Diabetic subjects
No. （male/female） 263 （146/117）
Age （years old） 59.4±11.6
Duration of diabetes （years） 11.4±8.9
FPG （mg/dL） 156.7±65.3
HbA1C （％） 9.6±2.2
BMI （kg/m2） 24.3±4.4
Right Median MCV （m/s） 50.7±4.9
Left Median MCV （m/s） （n＝214） 50.9±4.8
Right Median SCV （m/s） （n＝237） 47.0±7.5
Left Median SCV （m/s） （n＝198） 47.8±7.7
Right Peroneal MCV （m/s） （n＝188） 41.5±5.3
Left Peroneal MCV （m/s） （n＝191） 41.1±5.6
Right Sural SCV （m/s） （n＝159） 42.2±5.7
Left Sural SCV （m/s） （n＝163） 42.3±6.3
Therapy （n） Diet  10
OHA 113
Insulin 140
Anti-hypertensive drugs （＋/−） 176/87
Retinopathy （n） NDR 131
SDR 52
PDR 80
＊Diabetic neuropathy （＋/−） 45/67
FPG：fasting plasma glucose, HbA1c：hemoglobin A1c, 
BMI：body mass index, MCV：motor nerve conduction 
velocity, SCV：sensory conduction nerve velocity, OHA：
oral hypoglycemic agents, NDR：no diabetic retinopathy, 
SDR：simple diabetic retinopathy, PDR：proliferative dia-
betic retinopathy
＊：Diabetic neuropathy was evaluated only in 112 in the 
entire 263 patients. It was defined that the patients had dia-
betic neuropathy when the patients showed both “absent 
ATR” and “subjective symptoms assessed by pain or 
numbness of foot”.
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surface electrode was attached to the wrist （for medi-
an SCV） or lateral malleolus of the ankle （for sural 
SCV）, and supramaximal stimuli were applied to the 
index （second） finger （for median SCV） or to a 15-cm 
region proximal to the active electrode （for sural SCV）
. SCV was calculated from the conduction time divided 
by the distance. 
Measurement of the systolic blood pressure response 
to standing （DSBP）：DSBP was measured as the fall 
in systolic blood pressure when the subject arose from 
a supine to a standing position. Specifically, blood pres-
sure was measured several times in the afternoon, al-
ways more than 2 h after meals and after each subject 
had maintained a supine position at rest for more than 
10 min9）．Then the subject stood up slowly and blood 
pressure was measured again. The difference between 
the standing SBP and the final supine SBP was defined 
as DSBP, with a negative number indicating a de-
crease in blood pressure on standing.
Achilles tendon reflex （ATR）：The ATR was classi-
fied as “normal”, “weak” and “absent” based on the 
degree of the reflex, which was assessed subjectively 
by doctors. 
Determination of the coefficient of variation of the 
RR interval （CVRR）：CVRR was chosen for assessment 
of heart rate variability. Electrocardiographic （ECG） 
RR intervals were measured from 100 consecutive car-
diac cycles recorded mostly in the morning. During re-
cording, all subjects were at rest in a supine position 
and were instructed to maintain a respiratory rate 
above 9 breaths/min to decrease the effect of respira-
tory sinus arrhythmia. CVRR was calculated using the 
formula：CVRR＝（standard deviation of RR/mean RR）
×100. Patients with arrythmia were excluded from 
CVRR analysis. 
Plasma glucose, HbA1C, and serum lipid concentra-
tions：Fasting plasma glucose was evaluated by an au-
tomated glucose oxidase method （Glucose Auto Stat 
GA1160；Arkray, Kyoto, Japan）. HbA1C was measured 
by high-performance lipid chromatography （HPLC；
Hi-auto A1C, HA8150；Arkray）. This method only de-
tects HbA1C and the normal range is 4.3％ to 5.8％ . 
Serum total, low-density and high-density lipoprotein 
cholesterol （TC, LDL-C, and HDL-C） and serum trig-
lyceride （TG） concentrations were measured enzy-
matically. 
Blood pressure：Blood pressure was measured using 
a mercury sphygmomanometer in the morning at rest. 
Urinary albumin excretion （UAE）：UAE was mea-
sured once during the hospital stay by enzyme immu-
noassay in a 24-hr urine specimen maintained at 4℃. 
Albumin values were corrected for the urinary creati-
nine concentration. Creatinine clearance （Ccr） was 
also assessed using a 24-hr urine specimen.
Assessment of diabetic retinopathy：Diabetic retin-
opathy was assessed by each patient’s ophthalmologist 
in our hospital according to the Davis classification：10） 
no diabetic retinopathy （NDR）, simple diabetic retin-
opathy （SDR） or proliferative diabetic retinopathy 
（PDR）. 
Assessment of subjective symptoms of diabetic neu-
ropathy：These symptoms were evaluated by pain or 
numbness of foot, based on each patient’s declaration 
（“normal”, “mild”, and “severe”）．
Ethical considerations：All subjects gave informed 
consent to inclusion in the study. The study was per-
formed according to the guidelines in the Declaration 
of Helsinki.
Statistical methods：All data are presented as means
±standard deviation （SD）. The significance of correla-
tions between two variables was determined by simple 
regression analysis. UAE values were log10-trans-
formed because of their skewed distribution. 
Comparisons between two groups were made using an 
unpaired t test. For multiple comparisons, significances 
of individual differences were assessed using a Bonfer-
roni test. Multiple regression analysis with right medi-
an MCV as the dependent variable was performed in 
256 patients；the tested independent variables were 
age, BMI, duration of diabetes, SBP, diastolic blood 
pressure （DBP）, FPG, HbA1C, TC and TG. No combi-
nation with a strong correlation （R＞0.9） was found 
among these variables. A P value＜0.05 was accepted 
as indicating statistical significance.
???????
Correlations between right median MCV or right 
sural SCV with various parameters in type 2 diabetic 
patients are shown in Table 2, and the results of multi-
ple regression analysis of factors associated with right 
median MCV are summarized in Table 3. Right medi-
an MCV was detected in all 263 patients in the study 
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and showed significant negative correlations with age, 
diabetic duration and HDL-C. Right median MCV was 
also significantly negatively correlated with SBP and 
log UAE （Fig. 1A, B） and significantly positive corre-
lated with CVRR and DSBP.
Right median MCV showed strong positive correla-
tions with left median MCV and right median SCV 
（Fig. 2A, B） and a significant but relatively mild posi-
tive correlation with right peroneal MCV and right 
sural SCV （Fig. 2C）. In multiple regression analysis 
with right median MCV as the dependent variable, 
only SBP （P＜0.0001） and diabetic duration （P＝
0.0491） showed a significant association. In contrast, 
right sural SCV showed significant positive correla-
tions with DSBP, and significant negative correlations 
with SBP, DBP and log UAE. Of 215 patients who un-
derwent complete sural SCV measurements, right and 
left sural SCV were detected in 159 （74％） and 163 
164 DJMS
???????　 Multiple regression analysis with right Median 
MCV in 256 patients with type 2 diabetes 
Independent variable b F P 
Age （year） −0.0345 0.2491 0.6182
BMI （kg/m2） 0.0125 0.0390 0.8434
Duration （year） −0.1338 3.9103 0.0491＊
SBP （mm Hg） −0.3047 15.7635 ＜0.0001＊
DBP （mm Hg） 0.0528 0.5255 0.4692
FPG （mg/dL） −0.1156 3.3179 0.0697
HbA1C （％） −0.0268 0.1538 0.6953
TC （mg/dL） −0.0632 0.8757 0.3503
TG （mg/dL） −0.0355 0.2604 0.6103
（R2 for the model：14.7％）
b：standardized regression coefficient, F：F value, P：P 
value, R2：coefficient of determination.
BMI：body mass index, SBP：systolic blood pressure, 
DBP：diastolic blood pressure, FPG：fasting plasma 
glucose, HbA1c：hemoglobin A1c, TC：total cholesterol, 
TG：triglyceride 
???????　 Correlation between right median MCV or right sural SCV and various factors in type 2 
diabetic patients
Variant （n） Right Median MCV （n）Right Sural SCV
Age （years） （263）r＝−0.1334 P＝0.0306＊ （159）r＝0.0054 P＝0.9464
BMI （kg/m2） （263）r＝0.0362 P＝0.5584 （159）r＝0.0198 P＝0.8044
Duration （years） （263）r＝−0.2186 P＝0.0004＊ （159）r＝−0.1351 P＝0.0896
FPG （mg/dL） （263）r＝−0.1030 P＝0.0955 （159）r＝0.2068 P＝0.0088＊
HbA1C （％） （263）r＝0.0193 P＝0.7550 （159）r＝0.0815 P＝0.3074
SBP （mmHg） （263）r＝−0.3024 P＜0.0001＊ （159）r＝−0.1695 P＝0.0327＊
DBP （mmHg） （263）r＝−0.0880 P＝0.1547 （159）r＝−0.1773 P＝0.0254＊
TC （mg/dL） （259）r＝−0.1025 P＝0.0999 （158）r＝−0.0357 P＝0.6558
TG （mg/dL） （256）r＝−0.0532 P＝0.3966 （155）r＝−0.0836 P＝0.3012
HDL-C （mg/dL） （208）r＝−0.1366 P＝0.0492＊ （155）r＝−0.0110 P＝0.8920
LDL-C （mg/dL） （208）r＝0.0138 P＝0.8433 （155）r＝0.0150 P＝0.8530
U-CPR （pg/mL） （136）r＝0.1233 P＝0.1526 （65）  r＝0.1397 P＝0.2671
log10UAE （mg/g.Cr） （249）r＝−0.3890 P＜0.0001
＊ （150）r＝−0.2147 P＝0.0083＊
CVRR （％） （249）r＝0.2237 P＝0.0004
＊ （148）r＝0.0079 P＝0.9235
DSBP（mmHg） （158）r＝0.4195 P＜0.0001 （73）  r＝0.2690 P＝0.0213＊
Median MCV（Left）（m/s） （214）r＝0.8742 P＜0.0001＊ （158）r＝0.4460 P＜0.0001
Median SCV （m/s） （237）r＝0.6129 P＜0.0001＊ （152）r＝0.2524 P＝0.1050
Peroneal （MCV）（m/s） （188）r＝0.4025 P＜0.0001＊ （150）r＝0.5629 P＜0.0001＊
Sural SCV （m/s） （159）r＝0.4025 P＜0.0001＊ ─ ─
r：Pearson’s correlation coefficient, P：P value, P＜0.05 are defined as statistical significance. （n）：the 
number of patients 
BMI：body mass index, FPG：fasting plasma glucose, HbA1c：hemoglobin A1c, SBP：systolic blood 
pressure, DBP：diastolic blood pressure, TC：total cholesterol, TG：triglyceride, HDL-C：high density 
lipoprotein cholesterol, LDL-C：low density lipoprotein cholesterol, UAE：urinary albumin excretion, 
CVR-R：coefficient of variation of RR intervals, DSBP：systolic blood pressure response to standing
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patients （76％）, respectively. 
There were no-gender related differences in right 
median MCV, but significant decrease in right sural 
SCV in men’s patients was obtained （41.3±5.5 for 
men vs. 43.7±5.7 m/s for women, P＝0.008）. 
Regarding retinopathy in the 263 patients, the right 
median nerve MCV was 52.3±4.3 m/s in NDR pa-
tients, 50.7±5.1 m/s in SDR patients, and 48.1±4.7 
m/s in PDR patients. MCV differed significantly be-
tween NDR and SDR （P＝0.0030）, NDR and PDR （P
＜0.0001），and SDR and PDR （P＝0.0022） patients 
（Fig. 3）. The right median MCVs in patients treated 
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??????　The correlation between right median MCV and SBP（A）or log UAE（B）
??????　 The correlation between right median MCV and left median MCV（A）, 
right median SCV（B） and right sural SCV（C）
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with diet alone （n＝10），in those treated with an oral 
hypoglycemic agent （OHA） （n＝113）, and in those 
treated with insulin （n＝140） were 51.7±4.3, 51.9±
4.2, and 49.7±5.3 m/s, respectively；a significant dif-
ference was detected only between patients treated 
with an OHA and those treated with insulin （P＝
0.0003）．The right median MCV differed significantly 
in patients who did （n＝87） and did not （n＝176） re-
ceive antihypertensive drugs （49.8±4.8 and 51.1±4.9 
m/s, respectively；P＝0.0345）．
In patients who underwent right median MCV mea-
surement, ATR were evaluated only in 112 patients. 
The number of patients with normal, weak, absent 
ATR was respectively 58, 30 and 24；no significant 
difference in right median MCV was obtained among 
these patients’ groups. Regarding subjective symp-
toms, in these 112 patients, the number of patients as-
signed to “normal”, “mild”, and “severe” was respec-
tively 61, 31, and 20. Significant difference in right 
median MCV was detected only between patients with 
normal and mild symptoms （P＝0.0308）. 
??????????
In the current study, median and peroneal MCV and 
median and sural SCV were all close to the lower lim-
its described for healthy subjects 11）. These findings ap-
pear to be reasonable, since diabetes often causes dia-
betic neuropathy as a microangiopathy 1）. MCV showed 
significant negative correlations with age and diabetic 
duration, and the particularly strong correlation with 
diabetic duration is consistent with the importance of 
diabetic duration as a cause of diabetic neuropathy. 
Contrary to our expectation, median MCV did not cor-
relate with fasting plasma glucose （FPG） or HbA1c, 
which suggests that diabetic neuropathy is not always 
closely associated with short-term diabetic control. No-
tably, we found a significant negative correlation be-
tween median MCV and SBP, and SBP had the stron-
gest association with median MCV as a dependent 
variable in multiple regression analysis. In previous 
studies we have also found significant associations of 
SBP with CVRR
12） and QTc13）, which mainly reflect au-
tonomic nervous function. Therefore, our current and 
previous studies suggest that SBP closely influences 
diabetic neuropathy. Although these results are based 
on cross-sectional observation, we speculate that long-
term control of blood pressure may be more important 
for inhibition of progression of diabetic neuropathy, 
and that continuous treatment for hypertension may 
be important in prevention of progression of this com-
plication. A further prospective study is needed to ex-
amine this hypothesis.
It is well known that hyperlipidemia （or dyslipi-
demia） is closely associated with diabetic macroan-
giopathy based on atherosclerosis. In fact, in the 
CARDS study, LDL-C-lowering therapy with atorvas-
tatin in patients with type 2 diabetes with mild hyper-
l ipidemia dramatically reduced cardiovascular 
events14），suggesting that glycemic control and circu-
lating LDL-C levels are very important in progression 
of diabetic macroangiopathy. However, in the current 
study, median MCV did not correlate with circulating 
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　??????　The differnce in right median MCV among the NDR, SDR, and PDR patients
P =0.0022
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lipids levels, including TC, TG and LDL-C；only HDL-
C showed a weak negative correlation with median 
MCV. This suggests that circulating lipids levels are 
not strongly associated with diabetic neuropathy as re-
flected by median MCV. Furthermore, no correlation 
was observed between median MCV and BMI, sug-
gesting that MCV is also unaffected by the degree of 
obesity. Taken together, our results show that median 
MCV is closely associated with SBP and diabetic dura-
tion but not with FPG, HbA1c, lipids levels and BMI. 
Therefore, control of blood pressure and long-term 
（but not short-term） glycemic control may be espe-
cially important for inhibition of progression of diabetic 
neuropathy.
In the current study, we also investigated the associ-
ation of median MCV with retinopathy and nephropa-
thy. Median MCV was significantly lower in PDR pa-
tients compared with NDR or SDR patients, and there 
was also a significant negative correlation between me-
dian MCV and log UAE, which reflects the degree of 
diabetic nephropathy. These results indicate that pro-
gression of diabetic neuropathy proceeds in parallel 
with that of diabetic retinopathy and nephropathy, 
suggesting that it is important to evaluate retinopathy 
and nephropathy routinely in patients with a relatively 
low MCV. 
Sural SCV is known to be an especially sensitive pa-
rameter in nerve conduction velocity tests 15）, and in 
the current study sural SCV was detected in only 
about 75％ of patients with detectable MCV. Sural 
SCV was also closely correlated with variables related 
to diabetic complications, such as SBP and log UAE, 
but the correlations were relatively weak compared 
with those for median MCV. In addition, sural SCV did 
not correlate with age and diabetic duration, which 
were both significantly associated with median MCV. 
These results suggest that median MCV is more suit-
able than sural SCV as a standard marker in nerve 
conduction velocity tests. Furthermore, median MCV 
is generally easier to measure compared to sural SCV, 
which also supports the use of median MCV as a stan-
dard marker. Right median MCV was closely correlat-
ed with left MCV, and this suggests that measurement 
on one side only may be appropriate if patients do not 
have apparent organic lesions such as carpal tunnel 
syndrome, which can influence nerve conduction veloc-
ity. Furthermore, right median MCV and right median 
SCV were also closely correlated, and this suggests 
that measurement of median SCV may not always be 
needed in follow-up. Determination of sural SCV is im-
portant in the initial assessment of diabetic neuropa-
thy, since measurement of sural SCV is more sensitive 
than measurement of median SCV.
Based on the above results, we recommend that 
measurements of median MCV （which has a close cor-
relation with markers related to diabetic complica-
tions） and sural SCV （which has high sensitivity as a 
test for diabetic neuropathy） on both sides should be 
performed in an initial assessment of diabetic neuropa-
thy. Measurement of median MCV on one side only 
may be sufficient in subsequent follow-up to reduce 
the invasiveness of the tests.
In the current study, MCV and SCV were not inves-
tigated in age-matched healthy subjects, and the study 
was performed retrospectively based on data in previ-
ous studies, although without exclusion of specific pa-
tients. Furthermore, we could not evaluate SNAP am-
plitude in sural nerve or F wave minimum latency, 
which are important parameters for accurate diagnosis 
of neuropathy （15）. These were major limitations of 
the current study.
??????????
The study showed that median MCV is significantly 
negatively correlated with age, diabetic duration, SBP, 
and log UAE, but not correlated with FPG, HbA1c, or 
circulating lipid concentrations. Sural SCV was also 
significantly negatively correlated with SBP and log 
UAE, but the correlation was weak compared with 
those for median MCV. Sural SCV was not detectable 
in many patients who had a detectable median MCV. 
There were close positive correlations between right 
and left median MCV, and between right median MCV 
and right median SCV. Taken together, these results 
suggest that median MCV is more closely associated 
with markers related to diabetic complications, com-
pared with sural SCV, but that sural SCV is more sen-
sitive than median MCV for detection of diabetic neph-
ropathy. 
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